Sandoz's Gabapentin ANDA075428 Receives Abbreviated Approval
Sandoz has received an abbreviated approval for its ANDA075428 application for Gabapentin.
Published: July 23, 2026
Updated: July 23, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Anticonvulsant
Company: Sandoz
Asset: Gabapentin
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Sandoz
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The approval of Sandoz's Gabapentin ANDA075428 signifies a new entry into the generic market, which will intensify competition against existing branded products. This could lead to pricing pressures and shifts in market share that require close monitoring by portfolio teams.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timing and pricing strategies from Sandoz and competitors.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.